|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **NZ Clinical Trials** | **15 April 2025** |  |  |  |  |  |  |
| **Name of trial** **Registration** | **Outline of trial**  | **Date Registered** | **Status** | **Eligible CLL/SCL population**  | **NZ Locations**  | **Summary**  | **Follow links for more information and contact details**  |
| **BELLWAVE****NCT06136559** | Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) | 14/08/2024 | **Open** | People with chronic CLL/SLL who have not received any prior therapy and treatment is required | * Middlemore Hospital
* North Shore Hospital
* Waikato Hospital
 | A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated CLL/SLL (BELLWAVE-011) | [BELLWAVE](https://web.clintrialreferapp.com/SearchTrial/Details?trialId=UggW9H12FF8%3D&FrontEndUniqueId=b210b865568841838813a9336714bdf2323050422) |
| **RATIONALISE****ACTRN12622000359730** | To find out if oral antibiotics can be used instead of immunoglobulin (Ig) for preventing infections in patients with blood cancers | 06/08/2024 | **Open** | Patients having an acquired hypogammaglobulinaemia secondary to a haematological malignancy, and have received Ig treatment for over 6 months | * Wellington Hospital
 | A randomised controlled trial of continuing immunoglobulin therapy, or stopping with or without prophylactic antibiotics, on infection rate in patients with acquired hypogammaglobulinemia secondary to haematological malignancies. | [RATIONALISE](https://web.clintrialreferapp.com/SearchTrial/Details?trialId=0iFqtKbgPjc%3D&FrontEndUniqueId=b210b865568841838813a9336714bdf2323050422) |
| **LOXO-BTK-20030** **NCT05254743** | To compare the efficacy and safety of Pirtobritinib (LOXO-305) to ibrutinib in participants with CLL/SLL | 10/11/2023 | **Open** | Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria | * Dunedin Hospital
* Waikato Hospital
 | A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With CLL/SLL (BRUIN-CLL-314) | [LOXO-BTK-20030](https://web.clintrialreferapp.com/SearchTrial/Details?trialId=1vJw5WmYfM8%3D&FrontEndUniqueId=b210b865568841838813a9336714bdf2323050422) |
| **BGB-16673-302****NCT06846671** | To investigate use of BGB-16673 compared with investigator's choice (idelalisib plus rituximab or bendamustine plus rituximab or venetoclax plus rituximab retreatment) | 21/02/2025 | **Open / Pending in NZ ??** | Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria AND previously received treatment for CLL with a BTKi AND BCL2i | * North Shore Hospital
 | A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in patients with CLL Previously Exposed to Both BTK and BCL2 Inhibitors | [BGB-16673-302](https://web.clintrialreferapp.com/SearchTrial/Details?trialId=vYWCvLTcrtc%3D&FrontEndUniqueId=a1528abbafe84751a7cc8f404c54ebee1590844942) |
| **BGB-21447-101****NCT05828589** | Determine dosages for Bcl-2 Inhibitor BGB-21447 | 14/08/2024 | **Pending in NZ** | Relapsed/Refractory of CLL/SLL  | * Auckland Hospital
 | A Phase 1/1b Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies | [BGB-21447-101](https://web.clintrialreferapp.com/SearchTrial/Details?trialId=gUkrVNSda90%3D&FrontEndUniqueId=b210b865568841838813a9336714bdf2323050422) |
| **BGB-11417-301 (Celestial)** **NCT06073821** | Compare the duration patients live without CLL getting worse between participants who received Venetoclax + Obinutuzumab vs Sonrotoclax + Zanubrutinib  | 14/11/2023 | **Active, not recruiting** | Treatment naïve & needing treatment  | * Auckland Hospital
* Christchurch Hospital
* North Shore Hospital
* Tauranga Hospital
* Wellington Hospital
 | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukaemia | [BGB-11417-301](https://web.clintrialreferapp.com/SearchTrial/Details?trialId=7cQ9dN8hSWA%3D&FrontEndUniqueId=2bf57bdf416d49d29f808160921a4e4e1949110923) |
| **BGB-11417-101** **NCT04277637** | Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies | 20/02/2020 | **Active, not recruiting** | Relapse/refractory had at least 2 prior therapies | * Auckland Hospital
* North Shore Hospital
* Wellington Hospital
 | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies. (Sonrotoclax as monotherapy and also when given in combination with Zanubrutinib and Obinutuzumab) | [BGB-11417-101](https://web.clintrialreferapp.com/SearchTrial/Details?trialId=uTq3R8Diipo%3D&FrontEndUniqueId=b210b865568841838813a9336714bdf2323050422) |
| **AbbVie M14-728** **NCT02966756** | A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory CLL/SLL | 02/08/2019 | **Not recruiting in NZ Locations** | Relapsed or refractory Chronic Lymphocytic Leukaemia (CLL) in the presence of 17p deletion | * Christchurch Hospital
 | Phase 2, open-label, study, of venetoclax in participants with relapsed or refractory CLL/ SLL either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signalling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2) | [M14-728](https://web.clintrialreferapp.com/SearchTrial/Details?trialId=6Zj0zQGRflU%3D&FrontEndUniqueId=2bf57bdf416d49d29f808160921a4e4e1949110923) |